Tech Company Financing Transactions

Corvidia Therapeutics Funding Round

Corvidia Therapeutics secured a $60 million Series B funding round on 4/26/2018. Backers included Venrock, Andera Partners and Apple Tree Partners.

Transaction Overview

Company Name
Corvidia Therapeutics
Announced On
4/26/2018
Transaction Type
Venture Equity
Amount
$60,000,000
Round
Series B
Investors

Venrock (Lead Investor) (Karim Helmy)

Andera Partners

Apple Tree Partners (Seth Harrison)

Cormorant Asset Management

Fresenius Medical Care

HBM Healthcare Investments

MedImmune Ventures

Sofinnova Ventures (Graziano Seghezzi)

Proceeds Purpose
The financing will accelerate growth of Corvidia's ongoing clinical programs, expand scientific and market access capabilities and explore new treatment areas.

Company Information

Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
35 Gatehouse Dr.
Waltham, MA 02451
USA
Phone
(781) 205-4755
Website
www.corvidiatx.com
Email Address
[email protected]
Overview
Corvidia Therapeutics is a biotechnology company pioneering the next generation of cardiovascular therapies. Leveraging functional genomics, the company's founding team has decoded previously unrecognized genetic susceptibilities within general cardiovascular populations.
Profile
Corvidia Therapeutics LinkedIn Company Profile
Social Media
Corvidia Therapeutics Company Twitter Account
Company News
Corvidia Therapeutics News
Facebook
Corvidia Therapeutics on Facebook
YouTube
Corvidia Therapeutics on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Marc Garidel
  Marc Garidel LinkedIn Profile  Marc Garidel Twitter Account  Marc Garidel News  Marc Garidel on Facebook
Chief Scientific Officer
Michael Davidson
  Michael Davidson LinkedIn Profile  Michael Davidson Twitter Account  Michael Davidson News  Michael Davidson on Facebook
VP - Bus. Development
Ram Aiyar
  Ram Aiyar LinkedIn Profile  Ram Aiyar Twitter Account  Ram Aiyar News  Ram Aiyar on Facebook
VP - Manufacturing
GaoZhong Zhu
  GaoZhong Zhu LinkedIn Profile  GaoZhong Zhu Twitter Account  GaoZhong Zhu News  GaoZhong Zhu on Facebook
VP - Operations
Douglas Kling
  Douglas Kling LinkedIn Profile  Douglas Kling Twitter Account  Douglas Kling News  Douglas Kling on Facebook
VP - R & D
Matthew Devalaraja
  Matthew Devalaraja LinkedIn Profile  Matthew Devalaraja Twitter Account  Matthew Devalaraja News  Matthew Devalaraja on Facebook

 

 

Browse more venture capital transactions:

Prev: 4/26/2018: SpotOn venture capital transaction
Next: 4/26/2018: Savari venture capital transaction

 

Share this article

 

Where The Data Comes From

We do our best to document every notable VC transaction. VC investment data records reported here are sourced from company press releases and news coverage. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.